Company Encyclopedia
View More
name
Redhill Biopharma
RDHL.US
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults.
4.514 T
RDHL.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking107/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE428.09%A
    • Profit Margin-97.52%E
    • Gross Margin60.60%A
  • Growth ScoreB
    • Revenue YoY157.62%A
    • Net Profit YoY69.14%A
    • Total Assets YoY-16.57%E
    • Net Assets YoY-7332.79%E
  • Cash ScoreB
    • Cash Flow Margin-102.54%D
    • OCF YoY157.62%A
  • Operating ScoreC
    • Turnover0.47C
  • Debt ScoreE
    • Gearing Ratio124.01%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    RedHill Biopharma regains Nasdaq stockholders’ equity compliance

    RedHill Biopharma (RDHL) has regained compliance with Nasdaq as confirmed by Nasdaq on November 26, 2025. More on RedHill Seeking Alpha’s Quant Rating on RedHill Financial information for RedHill

    MSN·
    US
    RDHL
    +2.56%
    MSN·
    US
    RDHL
    +2.56%

    Redhill Biopharma Successfully Regains Compliance With Nasdaq Stockholders' Equity Requirement

    REDHILL BIOPHARMA SUCCESSFULLY REGAINS COMPLIANCE WITH NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT

    Reuters·
    US
    RDHL
    +2.56%
    Reuters·
    US
    RDHL
    +2.56%

    RedHill Biopharma Wins Final $10.5 Million Judgment Against Kukbo

    RedHill Biopharma Ltd. has won a final judgment of over $10.5 million against Kukbo Co. Ltd. from the New York Supreme Court. The award includes approximately $8.6 million in principal and around $1.9 million for legal fees. The principal judgment is final and enforceable, while the legal fees are subject to appeal until March 13, 2026. Both amounts will accrue 9% annual interest. Additionally, RedHill has secured a court order in Korea to prevent Kukbo from disposing of assets before the judgment is enforced.

    Reuters·
    US
    RDHL
    +2.56%
    Reuters·
    US
    RDHL
    +2.56%

    RedHill Biopharma Appeals Nasdaq Delisting Notice After Equity Boost

    RedHill Biopharma (RDHL) is appealing a Nasdaq delisting notice after receiving a notification for not meeting stockholders’ equity requirements. Following a transaction with Cumberland Pharmaceuticals, the company believes it now meets the criteria and remains listed pending a hearing. The latest analyst rating for RDHL is a Hold with a $1.50 price target. Spark’s AI Analyst rates RDHL as Neutral, citing challenging financial performance and potential for medium-term recovery despite negative profitability. RedHill focuses on drugs for gastrointestinal diseases, infectious diseases, and oncology.

    Tip Ranks·
    US
    RDHL
    +2.56%
    Tip Ranks·
    US
    RDHL
    +2.56%

    RedHill Biopharma notified by Nasdaq for non-compliance with stockholders' equity requirements on Oct 16, 2025.

    The Company was notified by The Nasdaq Stock Market LLC on October 16, 2025, due to failure to meet the minimum stockholders' equity requirements for continued listing under Listing Rule 5550(b)(1). This notification was regarding RedHill's transaction and signifies the Company's non-compliance with the stipulated regulations.

    Unusual Whales·
    US
    RDHL
    +2.56%
    Unusual Whales·
    US
    RDHL
    +2.56%
    © 2025 Longbridge｜Disclaimer